NO/HNO Releasing Derivatives of Chlorambucil and Aspirin
Publisher
The University of Arizona.Rights
Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.Abstract
Nitric oxide (NO) is a critical compound for many physiological processes and is closely connected to diseases such as cancer and pathophysiological conditions such as stroke and heart failure. NO synthesis is crucial for vasodilation and reduces blood clot formation. It is known to reduce glutathione (GSH), an inhibitor of cancer-therapy drugs, through oxidation of its thiol group. Combining chlorambucil, a chemotherapy drug that is used to treat chronic lymphocytic leukemia, and an NO releasing compound is projected to increase drug-therapy effectiveness on resistant cell line. Non-steroidal antiinflammatory drugs (NSAIDS) can also be combined with NO donors to create a drug that is both anti-inflammatory and anti-cancer.Type
textElectronic Thesis
Degree Name
B.S.Degree Level
bachelorsDegree Program
Honors CollegeBiochemistry and Molecular Biophysics